This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
After a Historic November, What Awaits ETFs in December?
by Sweta Killa
Let's delve into some of the major events of December and learn how to tap the opportune moments with ETFs.
Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.
5 International ETFs That Outstripped US Market in November
by Sweta Killa
November was a banner month for the global stock market despite the rising number of COVID-19 cases.
Pfizer/BioNTech Seek Marketing Nod for COVID-19 Vaccine in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.
Will Americans Get COVID-19 Vaccine Sooner Than Europeans?
by Kinjel Shah
Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe
Small Cap ETFs Deliver Big Gains for Investors
by Neena Mishra
November was the best month ever for the Russell 2000 index
5 Stocks in Dow ETF That Powered the Best Month Since 1987
by Sweta Killa
Amid rising COVID-19 cases, the Dow Jones wrapped up its best month in more than 30 years after hitting the major milestone of 30,000 for the first time last week.
AstraZeneca (AZN) Forxiga Approved in Japan for Heart Failure
by Zacks Equity Research
AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.
COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap
by Ritujay Ghosh
Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.
Stellar November Paves the Way for a Solid December: 5 Picks
by Tirthankar Chakraborty
Growth-oriented stocks like General Motors (GM), Malibu Boats (MBUU) and LaZBoy (LZB) are likely to do well this month on vaccine optimism and Yellen's possible appointment as US Treasury Secretary.
FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication
by Zacks Equity Research
FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.
Moderna (MRNA) Amends Coronavirus Vaccine Supply Deal in U.K.
by Zacks Equity Research
Moderna (MRNA) amends its present contract with the United Kingdom government to supply two million additional doses of its coronavirus vaccine candidate, mRNA-1273, upon approval.
Stock Market News for Nov 30, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Friday amid optimism surrounding COVID-19 vaccine.
5 of the Best Stocks to Buy Heading Into December
by Tirthankar Chakraborty
Progress toward a COVID-19 vaccine and Yellen likely to be selected for a top post certainly bode well for stocks in December. Some of the stocks worth investing in are Buckle (BKE) and Deere (DE).
Biotech ETF (XBI) Hits New 52-Week High
by Sanghamitra Saha
The biotech ETF hits a 52-week high on Nov 27. Can it soar further?
Markets Gear for a Different Black Friday
by Zacks Equity Research
Markets Gear for a Different Black Friday
Energy on Track for Its Best Month Ever: 5 ETF, Stock Winners
by Sweta Killa
The S&P 500 Energy Index is on track for the best month ever, gaining nearly 40%.
Black Friday 2020 Has a New Look
by Mark Vickery
$10.3 billion in Black Friday revenues are expected online today, growing 33% year over year.
Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal
by Kinjel Shah
AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.
Is $50 a Barrel the Next Stop for Rallying Crude Prices?
by Nilanjan Choudhury
The top gainers of the S&P 500 during the past month are all energy firms - Occidental Petroleum (OXY), Devon Energy (DVN), Diamondback Energy (FANG), Apache (APA) and TechnipFMC (FTI).
4 Consumer Discretionary Gainers From Positive Vaccine News
by Zacks Equity Research
Positive vaccine news along with a steady rise in consumer spending bode well for discretionary stocks, making it a good time to invest in names like Malibu Boats (MBUU) and YETI Holdings (YETI).
Moderna (MRNA) Inks Europe Supply Deal for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) signs a deal to supply up to 160 million vaccine doses to European Commission The vaccine is under review in Europe.
Wall Street Set to Close the Year Higher: 5 Top Growth Picks
by Zacks Equity Research
The stock market is poised to close the year positively, driven by a flurry of encouraging developments, making it a good time to invest in growth stocks like Beazer Homes (BZH) and Axcelis (ACLS).
Stock Market News for Nov 25, 2020
by Zacks Equity Research
The Dow crossed the 30,000 points mark on Tuesday as investors hoped for a swift economic recovery following progress in coronavirus vaccine development and transition of President-elect Joe Biden to the White House.
Dow Tops 30,000: 5 Stocks Driving the ETF
by Sweta Killa
The Dow Jones topped the 30,000 milestone for the first time on vaccine optimism, and improving prospects for the smooth transition of President-elect Joe Biden to White House.